Gabather AB (publ) (GABA) - Total Liabilities
Based on the latest financial reports, Gabather AB (publ) (GABA) has total liabilities worth Skr4.20 Million SEK (≈ $451.45K USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gabather AB (publ) - Total Liabilities Trend (2014–2025)
This chart illustrates how Gabather AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Gabather AB (publ) to evaluate short-term liquidity relative to the company's equity base.
Gabather AB (publ) Competitors by Total Liabilities
The table below lists competitors of Gabather AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OurLiving AB
ST:OURLIV
|
Sweden | Skr8.99 Million |
|
Aethlon Medical Inc
NASDAQ:AEMD
|
USA | $1.34 Billion |
|
Invion Ltd
AU:IVX
|
Australia | AU$1.24 Million |
|
Bonyf NV
PA:MLBON
|
France | €1.25 Million |
|
Thrive Tribe Technologies Ltd
AU:1TT
|
Australia | AU$659.69K |
|
NAYA Biosciences, Inc
NASDAQ:NAYA
|
USA | $33.70 Million |
|
China Pharma Holdings Inc
NYSE MKT:CPHI
|
USA | $7.49 Million |
|
PolyPlank publ AB
ST:POLY
|
Sweden | Skr21.55 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Gabather AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Gabather AB (publ) worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gabather AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gabather AB (publ) (2014–2025)
The table below shows the annual total liabilities of Gabather AB (publ) from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr4.69 Million ≈ $505.04K |
-21.89% |
| 2024-12-31 | Skr6.01 Million ≈ $646.56K |
-12.65% |
| 2023-12-31 | Skr6.88 Million ≈ $740.18K |
+107.54% |
| 2022-12-31 | Skr3.31 Million ≈ $356.64K |
-25.16% |
| 2021-12-31 | Skr4.43 Million ≈ $476.52K |
+33.74% |
| 2020-12-31 | Skr3.31 Million ≈ $356.32K |
+33.70% |
| 2019-12-31 | Skr2.48 Million ≈ $266.50K |
+7.99% |
| 2018-12-31 | Skr2.29 Million ≈ $246.80K |
-5.22% |
| 2017-12-31 | Skr2.42 Million ≈ $260.38K |
+55.05% |
| 2016-12-31 | Skr1.56 Million ≈ $167.93K |
+114.55% |
| 2015-12-31 | Skr727.31K ≈ $78.27K |
+38.47% |
| 2014-12-31 | Skr525.26K ≈ $56.53K |
-- |
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more